@inproceedings{oai:repo.qst.go.jp:00054291,
 author = {Kato, Takamitsu and Tsuda, Akihisa and Uesaka, Mitsuru and Fujimori, Akira and Kamada, Tadashi and Tsujii, Hirohiko and Okayasu, Ryuichi and 加藤 宝光 and 津田 晃久 and 上坂 充 and 藤森 亮 and 鎌田 正 and 辻井 博彦 and 岡安 隆一},
 book = {National Institute of Radiological Sciences Annual Report},
 month = {May},
 note = {Chordoma, a rare bone tumor, has been treated with surgery and/or radiation. However, only limited characterizations of chordoma cells are available due to the extremely long doubling time. To study the cell biology of chordoma, we derived and characterized a cell line with a shorter doubling time from the only available chordoma line U-CH1. After isolating a clone of U-CH1 cells with a short doubling time (U-CH1-N), cell growth, cell cycle distribution, DNA content, chromosome number, p53 status, and cell survival were examined after X-rays, heavy ions, camptothecin, mitomycin C, cisplatin and bleomycin. These data were compared with those of HeLa (cervical cancer) and U87-MG (glioblastoma) cells. The cell doubling times for HeLa, U87-MG and U-CH1-N were approximately 18 h, 24 h and 3 days respectively. Heavy ion irradiation killed all three lines more efficiently than x-rays. Relative biological effectiveness (RBE) at 10% survival for UCH-1-N was about 2.5 for 70keV/microm carbon and 4 for 200keV/microm iron ions. Among four chemicals, bleomycin showed the most marked cytotoxic effect on U-CH1-N. Our data provide the first chronological cell survival information using cells of chordoma origin and help explain the successful chordoma treatment by heavy ions.},
 pages = {1--6},
 title = {Radiobiology of Chordoma Cells},
 year = {2010}
}